Skip to content

Silgan Holdings SLGN Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Sonoco Products logo
Sonoco ProductsSON
Crown Holdings logo
Crown HoldingsCCK
Constellium logo
ConstelliumCSTM
Dow logo
DowDOW
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Reliance logo
RelianceRS

Other financials

Income statement

See full
Revenue$1.6B+6.4%
Gross profit$265.8M-1.7%
Net income$63.0M-7.2%
EPS (diluted)$0.60-4.8%

Balance sheet

See full
Cash & equivalents$435.4M+23.3%
Total debt$5.7B-2.1%
Total equity$2.3B+11.4%
Total assets$9.3B+6.3%

Cash flow

See full
Operating cash flow-$799.6M-17.0%
CapEx$82.4M-0.6%
Free cash flow-$882.0M-15.1%

Valuation

See full
Market cap$4.4B-25.1%
Enterprise value$9.63B-14.4%
P/E15.5×-4.8×
P/S0.7×-0.3×

Profitability

See full
Gross margin17.4%-0.2pp
Operating margin8.7%
Net margin4.3%-0.5pp
FCF margin4.7%-0.6pp

Returns & leverage

See full
Return on equity12.9%-1.6pp
Debt / equity2.4×-0.3×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Silgan Holdings in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Silgan Holdings’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Silgan Holdings's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Silgan Holdings's accrued liabilities, current?
Silgan Holdings (SLGN) reported accrued liabilities, current of $431.92M in Q1 2026.
How has Silgan Holdings's accrued liabilities, current changed year-over-year?
Silgan Holdings's accrued liabilities, current increased by 52.1% year-over-year, from $283.94M to $431.92M.
What is the long-term trend for Silgan Holdings's accrued liabilities, current?
Over 5 years (2020 to 2025), Silgan Holdings's accrued liabilities, current has grown at a 14.1% compound annual growth rate (CAGR), from $230.96M to $447.18M.